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Presentation 
A 30-year-old Caucasian male with no previous medical history presented to the emergency department 
with sudden onset chest pain brought on by exertion at work. He had never experienced similar 
episodes before, and chest pain was described as severe, mid-sternal, non-radiating, and was associated 
with palpitations, dyspnea, and near-syncope. Patient also reported unintentional weight loss of 40 
pounds over the 3 months leading up to presentation. Review of systems was positive for diaphoresis, 
increased anxiety, heat intolerance, and a mild hand tremor for several weeks. He denied cough, 
changes in vision or voice, nausea, vomiting, diarrhea, constipation, or abdominal pain. He reported no 
history of tobacco or illicit drug use and no family history of thyroid disease or autoimmune conditions. 
Assessment 
On examination, the patient was hypertensive (167/94 mm Hg), tachycardic (107 beats per minute), 
tachypneic (22 breaths per minute) with normal oxygen saturation (98%) on room air, and afebrile. 
Salient examination features included mild thyromegaly, resting fine tremor in outstretched hands, and 
symmetric hyperreflexia. No proptosis, cardiac, or pulmonary abnormalities were noted. 
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Electrocardiogram (ECG) demonstrated sinus tachycardia without ischemia, and troponin tests were 
negative for myocardial injury. Computed tomography (CT) angiography of the chest performed to 
assess for pulmonary embolism revealed a large (7.8 × 3.4 × 5.1 cm) anterior mediastinal mass, which 
was solid, without calcification or invasion of adjacent structures, and homogenous in appearance. No 
pulmonary embolism or mediastinal/hilar lymphadenopathy was seen and lung parenchyma was 
otherwise normal (Figures 1 A and B). Given the radiological findings, thymic carcinoma, metastatic 
germ cell tumor, thyroid cancer, and lymphoma formed the initial differential, diagnosis and the patient 
was admitted for further investigations and biopsy. 
In the interim, thyroid function tests were performed given the presenting symptoms, revealing 
hyperthyroidism with a thyroid stimulating hormone level of < 0.005 mIU/mL (0.550-4.780 mIU/mL), 
free thyroxine level of 3.05ng/dL (0.89-1.76 ng/dL), and total triiodothyronine level of 375 ng/dL (80-
200/dL). Endocrinology was consulted for further management and recommended testing confirmed 
Graves’ disease as the cause of hyperthyroidism because his thyroid-stimulating immunoglobulin and his 
thyroid-hormone receptor antibody titers were both elevated, respectively (479 % [Normal < 122%]; 
23.28 IU/L [Normal < 1.75 IU/mL]). CT-guided biopsy of the mediastinal mass was cancelled because the 
imaging characteristics in the presence of Graves’ disease were most consistent with Graves’ disease-
associated thymic hyperplasia. Close follow-up was recommended. 
Management 
Methimazole and propranolol were initiated with subjective improvement in symptoms, and the patient 
was discharged with close outpatient endocrine follow-up. Clinical course was complicated by 
methimazole-induced transaminitis, which necessitated discontinuation of thionamide therapy, and 
definitive therapy with radioactive iodine ablation (RAI) was pursued. The uptake of 24-hour I-123 was 
increased at 61% with homogenous gland enlargement. He was treated with 11.95 μCi of oral I-131 
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sodium iodide. Treatment was bridged using cholestyramine, prednisone, and propranolol until RAI was 
effective. Follow-up thyroid hormone levels normalized 1 month after RAI treatment. Chest CT repeated 
3 months after RAI (6 months after initial diagnosis) demonstrated significant reduction in the size (2.6 × 
2.5 × 3.2 cm) of the mediastinal thymic mass (Figures 2 A and B). Subsequent imaging 1 year after RAI 
therapy was administered demonstrated complete resolution of the thymic mass. 
Discussion 
Given this patient’s clinical presentation, concerns were initially raised of a cardiac or pulmonary 
etiology of his symptoms. Appropriate workup including CT imaging demonstrated a large anterior 
mediastinal mass, which was concerning for a malignancy. However, following the identification of 
Graves’ disease, the correct diagnosis of Graves’ disease-associated thymic hyperplasia was made 
before further unnecessary or invasive interventions. 
Graves’ disease-associated thymic hyperplasia is a known but often under-recognized finding associated 
with Graves’ disease. Although the exact pathophysiology of Graves’ disease-associated thymic 
hyperplasia is poorly understood, it is believed to be benign.1, 2 It is proposed that thyroid 
autoimmunity mediated by thyrotropin receptor antibodies and direct hormonal stimulation of thymic 
cortex in thyrotoxicosis may be the underlying mechanisms.3, 4 CT scan appearance of Graves’ disease-
associated thymic hyperplasia is typically that of a diffusely enlarged thymus gland in the anterior 
mediastinum with absence of calcifications and no invasion of surrounding structures. However, if 
suspicious radiographic features are identified, such as a discrete mass within the thymus or internal 
calcifications, then magnetic resonance imaging (MRI) with chemical shift ratio (CSR) is the next best 
step.1 CSR compares the signal intensity of the thymus to that of a paraspinal muscle. Signal intensity is 
lower in thymic hyperplasia because of normal fat infiltration in the hyperplastic thymus unlike in 
thymomas. Thymic biopsy should only be considered if initial CT appearance is suspicious, CSR on MRI is 
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worrying or unavailable, or if there is lack of regression of the mass after achieving euthyroid status in 
Graves’ disease.1 
There are a limited number of case reports in the current literature describing Graves’ disease-
associated thymic hyperplasia. A review by Haider et al described 47 case reports of Graves’ disease-
associated thymic hyperplasia.1 Of the 47 cases reviewed, 31 demonstrated similar findings and clinical 
courses to our patient with significant or complete regression of thymic hyperplasia after treatment of 
Graves’ disease within 6 weeks to 2 years of follow-up. Additionally, included within the review’s 
analysis, is a subset of the 17 case reports that evaluated tissue pathology, which were reassuringly all 
found to be benign.1 
In most documented cases of Graves’ disease-associated thymic hyperplasia, thymic hyperplasia 
resolves after initiation of medical therapy or definitive treatment, suggesting it is reasonable to follow 
patients with serial imaging until resolution.4, 5 Referral for possible invasive interventions should only 
occur if the mass persists despite resolution of thyrotoxicosis, or if there are additional associated 
concerning imaging features as detailed previously. Graves’ disease-associated thymic hyperplasia is a 
known complication of Graves’ disease and is often an incidental finding. With the increased use of 
imaging modalities in medicine, the frequency of these incidental discoveries will likely continue to 
increase. Therefore, clinicians need to be aware of the association between benign thymic hyperplasia 
and Graves’ disease to avoid unnecessary invasive interventions, counsel the patient appropriately, and 
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Figure 1. Images from chest computed tomography (CT) with intravenous contrast (pulmonary embolism 
protocol) with both axial (A) and coronal (B) views of the thymic mass at time of patient’s initial 




Figure 2. Images from follow-up chest computed tomography (CT) without intravenous contrast 
obtained 3 months after radioactive iodine ablation (RAI) therapy (6 months after initial diagnosis) with 
both axial (A) and coronal (B) views. Thymic dimensions measured 2.6 × 2.5 × 3.2 cm. 
